Assessing the de novo paradigm in sporadic early-onset Alzheimer disease trios

Journal Article (2026)
Author(s)

Aline Zarea (Université de Rouen)

Kevin Cassinari (Université de Rouen)

François Lecoquierre (Université de Rouen)

Olivier Quenez (Université de Rouen)

Camille Charbonnier (Université de Rouen)

Catherine Schramm (Université de Rouen)

Morgane Lacour (Université de Rouen)

Henne Holstege (Vrije Universiteit Amsterdam, Amsterdam UMC, Alzheimer Center Amsterdam, TU Delft - Electrical Engineering, Mathematics and Computer Science)

Marc Hulsman (Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, TU Delft - Electrical Engineering, Mathematics and Computer Science)

More Authors (External organisation)

Department
Intelligent Systems
DOI related publication
https://doi.org/10.1038/s41380-026-03665-6 Final published version
More Info
expand_more
Publication Year
2026
Language
English
Department
Intelligent Systems
Journal title
Molecular Psychiatry
Issue number
10
Volume number
31
Pages (from-to)
5879-5888
Page Views
26
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown. To assess the de novo mutation (DNM) hypothesis, we performed a nationwide recruitment of 37 novel sEOAD patients–unaffected parents trios. After assessing known monogenic genes, we performed trio-based exome sequencing and jointly analyzed novel trios with 12 previously reported ones. Of these, we selected 16 trios for genome sequencing. We identified three patients with a pathogenic DNM in APP or PSEN1. Then, from the 46 remaining trios, we identified 38 non-synonymous coding DNM and 4 de novo copy number variants (CNVs) in exome data. Four DNM (2 novel, in SPHK2 and DDR1) and bi-allelic inherited variants in two genes affected Alzheimer disease-related genes. No significant burden of rare coding variants in exome/genome data from 5643 EOAD cases and 16097 controls was identified using nested windows centered on each DNM position, at the transcript level. From genome data, one non-coding DNM was predicted to affect splicing in an AD-associated gene, PINX1. Overall, 48% probands carried ≥1 inherited risk factor with odds ratio (OR) > 1.5 and GWAS-defined Genetic Risk Scores (GRS) distribution was more consistent with random distribution than enrichment in higher scores in probands. We confirm that DNMs in known monogenic genes explain sEOAD in a minority of cases, while candidate DNMs in other genes might account for a small proportion of additional cases. The majority of sEOAD patients may have a complex etiology including multiple inherited variants, however, GRS might not explain most of its genetic component.